Rigel(US:RIGL) Seeking Alpha·2026-01-01 09:41Core Insights - The article discusses the author's long-term positive outlook on Rigel Pharmaceuticals (RIGL) and its product TAVALISSE, highlighting the company's promising pipeline and potential for growth [1]. Group 1: Company Overview - Rigel Pharmaceuticals has been under observation for seven years, with a focus on its innovative therapies and pipeline developments [1]. - The company is recognized for its commitment to developing breakthrough therapies in the biotech sector [1]. Group 2: Investment Perspective - The author expresses a bullish sentiment towards RIGL, indicating a potential buy opportunity noted in early 2019 [1]. - The investment strategy revolves around identifying innovative companies with catalysts for potential acquisitions, which aligns with Rigel's profile [1].